CA2012875A1 - Skin permeation enhancer compositions - Google Patents

Skin permeation enhancer compositions

Info

Publication number
CA2012875A1
CA2012875A1 CA2012875A CA2012875A CA2012875A1 CA 2012875 A1 CA2012875 A1 CA 2012875A1 CA 2012875 A CA2012875 A CA 2012875A CA 2012875 A CA2012875 A CA 2012875A CA 2012875 A1 CA2012875 A1 CA 2012875A1
Authority
CA
Canada
Prior art keywords
enhancer compositions
compositions
permeation enhancer
skin permeation
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2012875A
Other languages
French (fr)
Other versions
CA2012875C (en
Inventor
Chia-Ming Chiang
Gary W. Cleary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Chia-Ming Chiang
Gary W. Cleary
Cygnus Research Corporation
Cygnus Therapeutic Systems
Cygnus, Inc.
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23276050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2012875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chia-Ming Chiang, Gary W. Cleary, Cygnus Research Corporation, Cygnus Therapeutic Systems, Cygnus, Inc., Ortho-Mcneil Pharmaceutical, Inc. filed Critical Chia-Ming Chiang
Publication of CA2012875A1 publication Critical patent/CA2012875A1/en
Application granted granted Critical
Publication of CA2012875C publication Critical patent/CA2012875C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Abstract

Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The composition contains diethylene glycol monoethyl or monomethyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like. The compositions are particularly useful in conjunction with the transdermal administration of steroid drugs such as progestogens and estrogens.
Methods and drug delivery systems for using the enhancer compositions are provided as well.
CA002012875A 1989-03-22 1990-03-22 Skin permeation enhancer compositions Expired - Fee Related CA2012875C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US327,312 1989-03-22
US07/327,312 US4973468A (en) 1989-03-22 1989-03-22 Skin permeation enhancer compositions

Publications (2)

Publication Number Publication Date
CA2012875A1 true CA2012875A1 (en) 1990-09-22
CA2012875C CA2012875C (en) 1995-12-05

Family

ID=23276050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002012875A Expired - Fee Related CA2012875C (en) 1989-03-22 1990-03-22 Skin permeation enhancer compositions

Country Status (12)

Country Link
US (1) US4973468A (en)
EP (1) EP0464150B1 (en)
JP (1) JP2550441B2 (en)
KR (1) KR950010324B1 (en)
AT (1) ATE156995T1 (en)
AU (1) AU629331B2 (en)
CA (1) CA2012875C (en)
DE (1) DE69031309T2 (en)
DK (1) DK0464150T3 (en)
ES (1) ES2106029T3 (en)
FI (1) FI914391A0 (en)
WO (1) WO1990011064A1 (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
EP0523150A4 (en) * 1990-04-06 1993-09-29 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
JPH0827003A (en) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd Percutaneously absorbable pharmaceutical preparation
KR100382706B1 (en) 1994-09-14 2003-10-10 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Matrix for transdermal drug delivery
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
DK1563788T3 (en) 1995-08-29 2015-05-11 Nitto Denko Corp Microperforation of human skin for drug administration and monitoring purposes
DE19548332A1 (en) * 1995-12-22 1997-07-10 Rotta Res Bv hormone patches
AU2036297A (en) * 1996-03-20 1997-10-10 Glaxo Group Limited Topical formulations of aciclovir
IT1283102B1 (en) * 1996-06-06 1998-04-07 Permatec Nv THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
WO1998017315A2 (en) * 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CA2263334A1 (en) * 1996-10-30 1998-05-07 Sonal R. Patel Fatty acid esters of lactic acid salts as permeation enhancers
KR100215027B1 (en) * 1997-01-27 1999-08-16 성재갑 Composition for transdermal administration of steroid drugs and formulation containing same
KR100294084B1 (en) * 1998-06-02 2001-09-22 성재갑 Composition for transdermal administration of non-steroid drugs and formulation containing same
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
IT1294748B1 (en) 1997-09-17 1999-04-12 Permatec Tech Ag FORMULATION FOR A TRANSDERMAL DEVICE
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
WO1999032153A1 (en) 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
CA2326222C (en) * 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
FR2761600B1 (en) * 1998-06-19 2000-03-31 Oreal FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT
GB9825402D0 (en) † 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE485837T1 (en) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE INGREDIENTS WHICH GUARANTEES ADEQUATE THERAPEUTIC LEVELS
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10041478A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
DE60239528D1 (en) 2001-05-01 2011-05-05 Corium International Redwood City TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION
JP4116447B2 (en) 2001-05-01 2008-07-09 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス Hydrogel composition
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
DK1450804T3 (en) * 2001-11-29 2009-01-05 3M Innovative Properties Co Pharmaceutical formula rings comprising an immune response modifier
DE10159120B4 (en) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate and its use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
ES2612779T3 (en) * 2002-03-11 2017-05-18 Nitto Denko Corporation System of transdermal patches of drug administration, method of manufacture thereof and method of use thereof
US8116860B2 (en) * 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
WO2004017941A2 (en) * 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
EP1556501A4 (en) 2002-10-28 2009-04-08 Transform Pharmaceuticals Inc Transdermal assay with magnetic clamp
EP1426049B1 (en) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
JP4542743B2 (en) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 Solution pharmaceutical composition of pyridone derivatives
DE10261696A1 (en) 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20040241223A1 (en) * 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
US7816546B2 (en) * 2003-06-30 2010-10-19 Richter Gedeon Vegyeszeti Gyar Rt. Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime
WO2005007020A2 (en) 2003-07-03 2005-01-27 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
MXPA06003316A (en) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
CA2554649C (en) 2004-01-30 2015-10-27 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
WO2005077364A1 (en) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. Transdermal solifenacin preparation and method of improving transdermal permeability thereof
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
BRPI0513279A (en) * 2004-07-15 2008-05-06 Freedom 2 Llc modified fabric marking pigment and method for modifying fabric marking pigment
JP5270158B2 (en) 2004-08-05 2013-08-21 コリウム インターナショナル， インコーポレイテッド Adhesive composition
EP1853560A1 (en) 2005-02-23 2007-11-14 Psychenomics, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
DE102006050558B4 (en) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement
EP2182987A4 (en) * 2007-07-30 2011-11-02 Medacure International Inc Immune system modulator formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
US8609733B2 (en) * 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) * 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
US9119578B2 (en) 2011-04-29 2015-09-01 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
JP6078230B2 (en) 2009-03-02 2017-02-08 セブンス センス バイオシステムズ，インコーポレーテッド Techniques and devices related to blood sampling
WO2010101625A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Oxygen sensor
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
WO2011000210A1 (en) * 2009-07-01 2011-01-06 润和生物医药科技(汕头)有限公司 Composition of permeation enhancer and use thereof in transdermal drug delivery system
AU2010279384A1 (en) 2009-08-05 2012-03-01 Wake Forest University Compositions and methods for inducing apoptosis in prostate cancer cells
JP6022442B2 (en) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Male contraceptive compositions and methods of use
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US20130158482A1 (en) 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
EP2992827B1 (en) 2010-11-09 2017-04-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP2701600B1 (en) 2011-04-29 2016-06-08 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
WO2013027840A1 (en) * 2011-08-25 2013-02-28 ニプロパッチ株式会社 Hydrous adhesive skin patch
DE102011119043A1 (en) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprises an active substance-impermeable backing layer, self-adhesive reservoir with content of active substance, which is rotigotine or rotigotine derivative, and a removable protective layer
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013211876B2 (en) * 2012-01-26 2017-02-09 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
KR20150131330A (en) 2013-03-15 2015-11-24 더 칠드런스 메디칼 센터 코포레이션 neosaxitoxin combination formulations for prolonged local anesthesia
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20160287549A1 (en) 2013-11-22 2016-10-06 Genzyme Corporation Novel methods for treating neurodegenerative diseases
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (en) 2014-07-29 2017-10-31 Therapeuticsmd Inc Transdermal cream.
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
IL255769B2 (en) 2015-05-20 2023-09-01 Broad Inst Inc Shared neoantigens
WO2017004507A1 (en) * 2015-07-02 2017-01-05 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3923989A (en) * 1973-07-13 1975-12-02 Sandoz Ag Nitro substituted picolinonitriles as anti-bacterial and anti-fungal agents
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4440771A (en) * 1982-02-12 1984-04-03 The United States Of America As Represented By The Secretary Of The Army 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (en) * 1983-03-24 1986-01-31 Rhone Poulenc Sante NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
ZA87332B (en) * 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
CN1021196C (en) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) Prepn. method of progestin unit and system
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (en) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers

Also Published As

Publication number Publication date
DE69031309D1 (en) 1997-09-25
WO1990011064A1 (en) 1990-10-04
AU629331B2 (en) 1992-10-01
JP2550441B2 (en) 1996-11-06
KR920700601A (en) 1992-08-10
DK0464150T3 (en) 1997-09-15
EP0464150B1 (en) 1997-08-20
DE69031309T2 (en) 1998-01-08
JPH04505157A (en) 1992-09-10
AU5417490A (en) 1990-10-22
US4973468A (en) 1990-11-27
ES2106029T3 (en) 1997-11-01
KR950010324B1 (en) 1995-09-14
FI914391A0 (en) 1991-09-18
EP0464150A1 (en) 1992-01-08
EP0464150A4 (en) 1993-04-14
CA2012875C (en) 1995-12-05
ATE156995T1 (en) 1997-09-15

Similar Documents

Publication Publication Date Title
CA2012875A1 (en) Skin permeation enhancer compositions
CA2183543C (en) Sexual steroid-containing transdermal therapeutic systems
US5686097A (en) Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
MX9708722A (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers when drugs and/or permeation enhancers are unstable in combination during long-term storage.
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
WO2000045792A8 (en) Hydrogel particle formulations
CA2252772A1 (en) Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
EP0165696A3 (en) Improved transdermal dosage form
CA2207144A1 (en) A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
IL135258A0 (en) Bioadhesive compositions and methods for topical administration of active agents
GB2212723A (en) Skin permeation enhancer compositions using glycerol monooleate
CA2319515A1 (en) Anhydrous topical skin preparations
EP0279977A3 (en) Transdermal administration of progesterone, estradiol esters and mixtures thereof
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
CA2422974A1 (en) Medicaments based on progestins for dermal use
MY101536A (en) Anti-inflammatory and analgesic tape for external use
EP0971708B1 (en) Nimesulide gel systems for topical use
WO1995005137A1 (en) Transdermal delivery system using a combination of permeation enhancers
KR900011461A (en) Therapeutics using trypstatin as an active ingredient
NZ279226A (en) Desogestrel-containing transdermal application
JPS5750914A (en) Betamethasone external pharmaceutical
IE790098L (en) Solvent vehicle
IE900245L (en) Transdermal drug delivery composition
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
AU724308B2 (en) Transdermal therapeutic systems that contain sex steroids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed